Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
复制标题
来那度胺治疗骨髓纤维化伴骨髓化生。
作者：
A. Tefferi;Jorge Cortes;S. Verstovsek;R. Mesa;D. Thomas;T. Lasho;W. Hogan;M. Litzow;J. Allred;Dan Jones;C. Byrne;J. Zeldis;R. Ketterling;R. Mcclure;F. Giles;H. Kantarjian
We present results of 2 similarly designed but separate phase 2 studies involving single-agent lenalidomide (CC-5013, Revlimid) in a total of 68 patients with symptomatic myelofibrosis with myeloid metaplasia (MMM). Protocol treatment consisted of oral lenalidomide at 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) for 3 to 4 months with a plan to continue treatment for either 3 or 24 additional months, in case of response. Overall response rates were 22% for anemia, 33% for splenomegaly, and 50% for thrombocytopenia. Response in anemia was deemed impressive in 8 patients whose hemoglobin level normalized from a baseline of either transfusion dependency or hemoglobin level lower than 100 g/L. Additional treatment effects in these patients included resolution of leukoerythroblastosis (4 patients), a decrease in medullary fibrosis and angiogenesis (2 patients), and del(5)(q13q33) cytogenetic remission accompanied by a reduction in JAK2(V617F) mutation burden (1 patient). Grade 3 or 4 adverse events included neutropenia (31%) and thrombocytopenia (19%). We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities.
登录
查看更多内容
影响因子：
20.3
作者：
Steensma, DP;Dewald, GW;Tefferi, A
通讯作者：
Tefferi, A
影响因子：
20.3
作者：
Ruben A. Mesa;C. Hanson;S. V. Rajkumar;G. Schroeder;A. Tefferi
通讯作者：
Ruben A. Mesa;C. Hanson;S. V. Rajkumar;G. Schroeder;A. Tefferi
影响因子：
3.5
作者：
Trotti, A;Colevas, AD;Rubin, P
通讯作者：
Rubin, P
影响因子：
158.5
作者：
List, A;Kurtin, S;Zeldis, JB
通讯作者：
Zeldis, JB